Suggested remit: To appraise the clinical and cost effectiveness of glofitamab with gemcitabine and oxaliplatin within its marketing authorisation for treating relapsed or refractory diffuse large B-cell lymphoma.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6202
Provisional Schedule
- Draft guidance: 1:
- 29 July 2025 - 19 August 2025
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Roche Products (glofitamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Blood Cancer UK
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- AbbVie (epcoritamab) (confidentiality agreement signed, participating)
- Bristol-Myers Squibb Pharmaceuticals (etoposide) (confidentiality agreement signed, participating)
- Kite, a Gilead company (axicabtagene ciloleucel) (confidentiality agreement signed, participating)
- Swedish Orphan Biovitrum (loncastuximab tesirine) (confidentiality agreement signed, participating)
- Accord Healthcare (bendamustine, etoposide, gemcitabine, prednisolone, oxaliplatin) (confidentiality agreement not signed, not participating)
- Actavis (bendamustine, etoposide, gemcitabine, prednisolone) (confidentiality agreement not signed, not participating)
- Advanz Pharma (prednisolone) (confidentiality agreement not signed, not participating)
- Aspen (chlorambucil) (confidentiality agreement not signed, not participating)
- Baxter Healthcare (cyclophosphamide, ifosfamide) (confidentiality agreement not signed, not participating)
- Consilient Health (dexamethasone) (confidentiality agreement not signed, not participating)
- Dr Reddy’s Laboratories UK (bendamustine) (confidentiality agreement not signed, not participating)
- Eli Lilly and Company (gemcitabine) (confidentiality agreement not signed, not participating)
- Hospira UK (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating)
- Medac UK (bendamustine, etoposide, lomustine, oxaliplatin) (confidentiality agreement not signed, not participating)
- Napp Pharmaceuticals (bendamustine, rituximab) (confidentiality agreement not signed, not participating)
- Pfizer (gemcitabine, vincristine) (confidentiality agreement not signed, not participating)
- Ranbaxy (UK), a Sun Pharmaceutical Company (gemcitabine) (confidentiality agreement not signed, not participating)
- Roche (glofitamab, polatuzumab vedotin, rituximab) (confidentiality agreement not signed, not participating)
- Sandoz (cyclophosphamide, rituximab) (confidentiality agreement not signed, not participating)
- Seacross pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
- Teva Nederland B.V. (bleomycin) (confidentiality agreement not signed, not participating)
- Zentiva (bendamustine, prednisolone) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 July 2025 | Committee meeting |
| 25 November 2024 | Invitation to participate |
| 26 July 2024 | Please note that following on from information received from the company this appraisal has been rescheduled to align with latest regulatory expectations and the appraisal is now anticipated to begin in late November 2024. |
| 19 March 2024 - 18 April 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6202 |
| 19 March 2024 | In progress. Scoping commenced. |
| 08 February 2024 | Please note that following on from information received from the company, the timelines for this appraisal have now been revised and the appraisal is now anticipated to begin in late July 2024. |
| 16 October 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 25 October 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual